Investors Overview

Investors Overview

Our Mission

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.

Learn more about BD

News Releases

11/25/2019

Summary Toggle BD Board Declares Dividends

FRANKLIN LAKES, N.J. , Nov. 25, 2019 /PRNewswire/ -- The Board of Directors of BD ( Becton, Dickinson and Company ) (NYSE: BDX) has declared a quarterly dividend of $0.79 cents per common share, an increase of 2.6 percent from the previous quarter. The dividend will be payable on December 31, 2019

PDF Version
11/22/2019

Summary Toggle BD to Present at Evercore ISI 2nd Annual HealthCONx Conference

FRANKLIN LAKES, N.J. , Nov. 22, 2019 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 2 nd Annual HealthCONx Conference on Wednesday, December 4, 2019 , at 11:45 a.m. ET .

PDF Version
11/21/2019

Summary Toggle BD Launches Enhanced Antimicrobial Stewardship Analytics Capabilities

New antimicrobial stewardship technology will be demonstrated at ASHP 2019 Midyear Meeting FRANKLIN LAKES, N.J. , Nov. 21, 2019 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced its latest advancement in combating

PDF Version
11/15/2019

Summary Toggle BD Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Investment Corporation

FRANKLIN LAKES, N.J. , Nov. 15, 2019 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX) announced today that it has been notified of an unsolicited mini-tender offer by TRC Capital Investment Corporation ("TRC") to purchase up to 500,000 shares of BDX common stock at a price of

PDF Version
11/14/2019

Summary Toggle BD to Present at Jefferies 2019 London Healthcare Conference

FRANKLIN LAKES, N.J. , Nov. 14, 2019 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 , at 6:20 a.m. ET .

PDF Version
11/12/2019

Summary Toggle BD Submits Pre-Market Approval Supplement to FDA for BD Onclarity™ HPV Test with Extended Genotyping Capabilities

FRANKLIN LAKES, N.J. , Nov. 12, 2019 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration ( FDA ) for an expanded version

PDF Version